Bone metastasis of lung adenocarcinoma (AC) is a frequent complication of advanced disease. The purpose of this study was to identify key mediators conferring robust prometastatic activity with clinical significance. We isolated highly metastatic subpopulations (HMS) using a previously described in vivo model of lung AC bone metastasis. We performed transcriptomic profiling of HMS and stringent bioinformatics filtering. Functional validation was assessed by overexpression and lentiviral silencing of single, double and triple combination in vivo and in vitro. We identified HDAC4, PITX1 and ROBO1 that decreased bone metastatic ability after their simultaneous abrogation. These effects were solely linked to defects in osseous colonization. The molecular mechanisms related to bone colonization were mediated by non-cell autonomous effects that include the following: (1) a marked decrease in osteoclastogenic activity in vitro and in vivo, an effect associated with reduced pro-osteoclastogenic cytokines IL-11 and PTHrP expression levels, as well as decreased in vitro expression of stromal rankl in conditions mimicking tumor-stromal interactions; (2) an abrogated response to TGF-b signaling by decreased phosphorylation and levels of Smad2/3 in tumor cells and (3) an impaired metalloproteolytic activity in vitro. Interestingly, coexpression of HDAC4 and PITX1 conferred high prometastatic activity in vivo. Further, levels of both genes correlated with patients at higher risk of metastasis in a clinical lung AC data set and with a poorer clinical outcome. These findings provide functional and clinical evidence that this metastatic subset is an important determinant of osseous colonization. These data suggest novel therapeutic targets to effectively block lung AC bone metastasis.
INTRODUCTION
Bone metastasis is a frequent complication of non-small cell lung cancer associated with dismal prognosis. [1] [2] [3] [4] As many as 30-40% of lung cancer patients experience significant morbidity as a result of skeletal related events, including pain, spinal cord compression associated with pathological fractures and other metabolic disorders that entail a significant reduction in life expectancy. 4, 5 Dissemination of tumor cells requires the acquisition of cell functions such as invasion and motility, survival in circulation and the ability to arrest in the osseous milieu and form secondary outgrowths. 6 The completion of each step involves the collective activity of a complex multigenic program that also allows adaptation to the stringent conditions imposed in the target organ. Besides intrinsic tumor functions, this multifaceted process is heavily modulated by biological and mechanical factors derived from the selective pressure exerted by the microenvironment. At the osseous site, colonization by malignant cells proceeds by the tumor-induced secretion of osteoclastogenic factors such as IL-11, IL-8, PTHrP that stimulate osteoclast-mediated bone resorption. 7 In turn, this process liberates active TGF-b from the bone matrix, which fuels tumor cells to perpetuate the secretion of osteoclaststimulating factors, thus instituting a self-feeding cycle implicated in destructive bone lesions. 8 In addition, deleterious proteolytic degradation of bone matrix also occurs through the concomitant tumor secretion of MMP and other proteases exacerbated at the tumor-stromal interphase. 9 In lung cancer bone metastases, several critical mediators of the metastatic process required for one or several discrete steps have been characterized. For instance, collagen receptor DDR1, associated with poor prognosis in lung cancer patients, enhanced tumor cell survival and mediated cell engagement and colonization in the bone. 10 More recently, receptor of activated protein C (EPCR) promoted tumor cell survival and was correlated with the clinical outcome in lung adenocarcinoma (AC) patients. 11 Genetic silencing or antibody blockade of EPCR led to strong abrogation of bone metastasis. Similarly, activation of signaling pathways in tumor cells regulating large downstream gene networks has been shown to exert potent activity driving metastasis. Hyperactive WNT/TCF signaling mediates lung AC metastasis to the bone and brain. 12 Similarly, perturbation of critical pathways in the host bone milieu, such as PDGFR/VEGFR axis, severely impairs bone metastatic colonization. 13 In all cases, inhibition of these molecular targets in preclinical animal models leads to a substantial reduction of osseous metastasis. Yet, metastases proceed inexorably indicating that crucial gene regulators at the crossroads of multiple critical signaling pathways might be targeted to attain more salient antimetastatic effects. Identification of critical components modulating large regulatory effectors could be of great biological relevance and potential therapeutic interest, but so far few have been identified.
In this study, using comparative transcriptomic analysis in a model of lung cancer bone metastasis, we identified a gene signature of three genes that cooperatively confers high osseous metastatic activity by inducing strong osteoclast and proteolytic activities. Moreover, this signature also sensitizes tumor cells to TGF-b-induced response. Consistently, high levels of this triple gene subset were associated with poor survival in AC patients. These findings provide experimental and clinical evidence of critical targets involved in metastasis progression.
RESULTS

Isolation of highly-metastatic subpopulations
We used a model of human AC A549 cells that displayed high proclivity to form bone metastasis. After intracardiac (i.c.) inoculation of luciferase-labeled A549 parental cells into athymic nude mice, several subpopulations that metastasized to the hind limbs were isolated, expanded in vitro, and their metastatic activity was assessed by subsequent i.c. re-inoculation. After two in vivo passages, osseous metastatic activity of different subpopulations was evaluated using Kaplan-Meier curves. Compared with the parental control cells, several subpopulations named M1, M3 and M4 decreased animal survival ( Figure 1a ). Consistent with these results, computerized X-ray image analysis revealed an increased area of bone metastasis in the hind limbs induced by M1, M3 and M4 subpopulations (Figure 1b ). To assess tumor burden, we isolated metastatic cells by bone marrow 'flushing', and conspicuous single-cell-derived colonies from each animal were counted. Subpopulations M1, M3 and M4 induced a more abundant yield of single-cell-derived colonies than did the parental cell line (Figure 1c ). Parental and derived subpopulations displayed similar in vivo growth (Figure 1d ), which indicated that the increased metastatic ability observed in vivo was due to the acquisition of a bone metastatic phenotype.
High levels of ROBO1, HDAC4 and PITX1 characterize the phenotype of highly metastatic subpopulations lung AC cells To identify genes involved in lung AC metastasis to bone, we performed a transcriptomic analysis comparison between highly metastatic subpopulations (HMS) and parental cells. Robust bioinformatics filtering identified a gene signature of differentially overexpressed genes (Supplementary Table S1 ). On the basis of stringent bioinformatics tools 9 and biological criteria, we selected a subset of genes that included ROBO1 (roundabout, axon guidance receptor, homolog 1), HDAC4 (histone deacetylase 4) and PITX1 (paired-like homeodomain1). HMS expressed high levels of these genes subset as assessed by western blot (Figure 2a) and RT-qPCR analysis (Figure 2a and Supplementary Figure S1a) . Lack of an optimal anti-ROBO1 antibody precluded its analysis by western blot.
To test their functional relevance, we individually depleted the expression of each gene using three specific shRNAs. We selected the most efficient shRNA for further experiments. Western blot analysis revealed abrogation of PITX1 and HDAC4 protein levels, whereas a dramatic downregulation of ROBO1 expression levels was observed by RT-qPCR (Figure 2b ). To assess their contribution to bone prometastatic activity, we injected single-knockdown (KD) cells into the left cardiac ventricle of athymic nude mice. Single KD did not affect the time of latency in the appearance of bone metastatic lesions (Figure 2c ). Bioluminescence imaging (BLI) revealed a slight decrease, but not statistically significant, in HDAC4 and PITX1 KD cells (Figure 2d ). Similarly, a mild decrease in lesion area of hind limbs was observed, but differences did not reach statistical significance (Figure 2d ). Thus, abrogation of gene expression for each single gene did not contribute significantly to the prometastatic activity in vivo.
Double and triple KD decreases prometastatic activity Next, we posited that simultaneous inhibition of multiple genes could be required to effectively target bone metastasis. Double Figure S1c) . However, no significant differences were detected in overall survival (Supplementary Figure S1d) . To investigate whether triple KD gene combination had a greater effect on survival, we intracardially injected triple KD (3KD) cells. Animals inoculated with 3KD cells showed a significantly longer latency time for the appearance of metastasis assessed using Kaplan-Meier curves (Figure 3a , upper panel). Notably, control animals showed a marked tumor-induced weight loss, whereas mice inoculated with 3KD cells showed slight increase in body weight observed at the end of the experimental period ( Figure 3a , bottom panel). These results were associated with an overt decrease in bone colonization of hind limbs assessed by BLI in mice inoculated with 3KD cells (Figure 3b ). Consistently, X-ray image analysis showed a marked reduction in bone lesions in mice injected with 3KD cells as compared with control groups and revealed preserved cortical and trabecular bone in the metaphyseal region of these animals ( Figure 3c ). In contrast, overt osteolytic lesions were detected in tibiae and femora of control mice ( Figure 3c ). Importantly, all these observations could not be explained by cell autonomous differential growth kinetics, as 3KD cells showed similar in vitro cellular proliferation and clonogenic ability as compared with control cells (Supplementary Figure S2a) . Similarly, 3KD cells form tumors of similar size as control cells, after subcutaneous injection (Supplementary Figure S2b) . To assess whether the observed low prometastatic activity was caused by a decrease in the ability of cells to infiltrate and survive at early stages of osseous homing, we killed the mice 7 days after i.c. cell inoculation. No obvious differences in bone metastatic Figure S2c) and bone marrow flushing of hind limbs (data not shown), indicating that 3KD did not significantly contribute to bone homing metastatic activity. Taken together, these data indicate that HDAC4, PITX1 and ROBO1 cooperatively contribute to the metastatic activity of lung cancer cells by mechanisms independent from cell autonomous proliferation and homing activity.
As complementary validation of these findings, we simultaneously overexpressed these pro-metastatic genes in parental A549 cells (Supplementary Figure S3a) . Limitations of the maximum packaging limit of the retroviral system for ROBO1 precluded the development of the triple overexpressor. In line with previous findings, i.c. inoculation of double overexpressor PITX1 and HDAC4 led to a substantial increase in metastatic tumor burden assessed by BLI and the formation of overt osteolytic lesions as compared with control mice (Supplementary Figures  S3b and c) . Slight decrease in cell growth kinetics of HDAC4/PITX1 cells was detected in vitro (Supplementary Figure S3d) . Thus, these findings further support the relevance of HDAC4 and PITX1 genes as robust prometastatic drivers of bone metastasis in lung AC.
3KD appeases osseous colonization
To assess whether prometastatic activity to the bone was mediated by the ability of cells to colonize the osseous compartment, tumor cells were injected directly into the tibial bone. Three weeks post injection, BLI showed an overt decrease in tumor burden of tibiae in animals injected with 3KD cells as compared with control cells (Figure 4a ). Similarly, assessment of X-ray imaging showed that 3KD cells displayed an impaired ability to colonize the bone compartment, whereas striking osteolytic lesions were detected in tibiae of control mice ( Figure 4b ).
Osteoclastogenic activity fostered by tumor cells is a major mechanism of bone degradation in osseous metastases. 4 Thus, we studied whether the reduction of osteolytic lesions in our in vivo model was related to an impairment of prosteoclastogenic activity. Consistent with previous findings, analysis of tibiae harboring 3KD cells revealed a dramatic decrease in the number of TRAP þ cells at the tumor-bone interface ( Figure 4c ). To test whether differences in tumor burden were due to changes in cell apoptosis or proliferation within the bone microenvironment, immunohistochemical staining for Ki-67 and cleaved caspase-3 were performed. Few apoptotic cells were detected, and no differences were observed between bone metastatic tumors derived from 3KD and control cells (data not shown). Interestingly, a low percentage of Ki-67-positive cells was observed in 3KD tumors (Figure 4d ). Taken together, these data suggest that HDAC4, ROBO1 and PITX1 cooperatively contribute to mediate osseous colonization in response to microenvironmental factors acting on tumor cells.
3KD cells regulate non-cell autonomous mechanisms critical for bone degradation To explore whether the mechanism of osteoclast activation was induced by soluble factors released in the tumor microenvironment, we performed an in vitro osteoclastogenesis assay with bone murine macrophages in the presence of conditioned medium (CM) of cells in coculture with the bone stromal cell line ST-2. Incubation of bone marrow macrophages with CM derived from 3KD cells in the presence of ST-2 cells led to a decrease in the size of multinucleated TRAP þ cells, as compared with CM derived from control cells (Figure 5a ). Together, these findings suggest that the three-gene signature tightly controls non-cell autonomous mechanisms involving osteoclastogenic activity to promote osteolytic lesions.
Next, we investigated the molecular mechanisms associated with the decreased osteoclast formation. To this end, expression levels of critical prosteoclastogenic factors such as RANKL, IL11 and PTHrP were studied. First, we observed that murine rankl was expressed by ST-2 stromal cells in coculture with tumor cells, despite the lack of rankl expression by ST-2 cells individually cultured (data not shown). Interestingly, 3KD cells incubated with ST-2 cells resulted in a significant attenuation of rankl expression by ST-2 cells (Figure 5b, upper panel) . Second, 3KD cells expressed lower levels of osteoclastogenic factors PTHrP and IL11 in both single (Figure 5b , middle and bottom panels) and coculture conditions (data not shown). More importantly, upon TGF-b stimulation, expression levels of PTHrP were decreased in shROBO1 cells (Po0.001), whereas, in shPITX1cells, PTHrP levels showed a stunted abrogation (Po0.001). This difference was further diminished in triple KD cells as compared with their respective controls (Figure 5c ) indicating an additive effect of combined decreased levels in ROBO1 and PITX1 KD cells. Furthermore, downregulation of IL11 expression levels in stimulated conditions was observed for all three single-KD cells, whereas a more pronounced decrease was detected in triple-KD cells (Figure 5c ), suggesting that each gene differentially contributes to PTHrP and IL11 levels after TFG-b stimulation. Interestingly, enhanced expression levels of IL11 were also detected upon TGF-b stimulation in double overexpressor HDAC4/PITX1 (Supplementary Figure S3e) . These data indicate that this triple gene subset is required in tumor cells for proper PTHrP and IL11 expression under TGF-b-stimulated conditions.
It has been well established that MMPs significantly contribute to bone matrix degradation in bone metastases.
14 Although type I Collagen can be degraded by several MMPs, we have previously shown that MMP-3/MMP-10 activities are rapidly induced upon tumor-stromal interactions. 15 Global MMP activity of 3KD cells cultured alone was unaffected (data not shown). However, in line with previous findings, increase in MMP activity using a fluorogenic peptide for a MMP-3 and À 10 in the presence of ST-2 cells was lower in coculture incorporating 3KD cells (Figure 5d ). These data confirmed that triple combination of genes contributes to tumor-stromal associated metalloproteolytic activity and suggest regulation of non-cell autonomous mechanisms by the three-gene signature.
TGF-b signaling is altered in triple gene KD cells As matrix-derived TGF-b has a pivotal role in tumor-induced osteolytic lesions, we explored whether this gene signature was induced by TGF-b. Incubation of tumor cells with increasing doses of TGF-b did not show significant changes in PITX1 and HDAC4 expression levels (Supplementary Figure S4) .
Two of the genes identified chromatin modifier HDAC4 and the transcriptional factor PITX1 could modulate large gene network; we explored their contribution to the TGF-b signaling pathway. To this end, we analyzed the activation status of R-SMADs in silenced tumor cells. Upon TGF-b treatment, no significant changes were observed in single PITX1 KD cells in SMAD 2 and 3 activation (Supplementary Figures S5a and b) , whereas single ROBO1 KD cells showed no changes in SMAD 2 activation and a fast activation of Smad 3 at 15 min that diminished at 30 min (Supplementary Figures S5a and c) . In contrast, a robust SMAD 2 and 3 activation was observed in HDAC4 KD cells 30 min after TGFb stimulation (Figure 6a ). This activation was maintained in double HDAC4/PITX1 KD cells (Supplementary Figure S6b) , but not in other double combinations (Supplementary Figures S6a and c) except for the HDAC4/ROBO1 KD where, similarly to single ROBO1KD cells, a strong activation was observed for SMAD3 at 15 min that further declined at 30 min (Supplementary Figure S6a) . Interestingly, at the same time point, 3KD cells displayed an Figure S6d) . Taken together, these data indicate that the triple gene combination is required for proper sensitivity of TGF-b signaling. These results also suggest that triple HDAC4, PITX1 and ROBO1 combination is required for proper R-Smads activation and together contributes to unimpaired TGF-b response in tumor cells.
Combined high HDAC4 and PITX1 expression predicts metastasis risk in lung AC patients To investigate the clinical implications of the three-gene signature in lung AC metastasis, we used a previously published database 12 from a lung AC cohort that includes information on lung tumor progression to metastasis for 107 lung AC patients (Supplementary Table S2a ). Normalized expression values of single probe sets were divided into high-expression and lowexpression groups of patient using median as a cutoff. A shorter time of metastasis-free survival was found in HDAC4 and PITX1 high-expression patients as compared with low expressors (Figure 7a ). Classification according to ROBO1 levels showed no significant differences (data not shown). Interestingly, clinical samples with higher levels of both HDAC4 and PITX1 (24 of 107 lung AC patients) showed a stronger correlation with shorter latency time in metastasis events (Figure 7b) . Discrimination shown by triple combination was significant, although it was not as robust as the double combination (Figure 7c) . Furthermore, using an independent cohort of 442 lung cancer patients from Shedden 16 ( Supplementary Table S2b ), Kaplan-Meier survival analysis showed similar results (Supplementary Figures S8a-c) . These data indicate that combined high HDAC4, PITX1 and ROBO1 transcriptomic levels discriminate patients at higher risk of metastasis development and poor survival.
DISCUSSION
This study identified a subset of genes involved in the osseous prometastatic activity of lung AC. Abrogation of this gene signature entailed decreased tumor-induced osteolytic lesions, an effect partially mediated by impaired osteoclastogenesis. This finding was associated with downregulation of several key prosteoclastogenic factors including a cell autonomous decrease in PTHrP and IL11 production. Moreover, stromal induction of rankl mediated by tumor-stromal interactions was also severely impaired in coculture with 3KD cells. These effects might explain the marked abrogation of osteolysis and tumor burden induced by 3KD cells and revealed the significance of these genes as regulators of the tumor-induced osteoclastogenic process. As a consequence, it is tempting to speculate that decreased bone resorption could lead to the low release of bone matrix-derived TGF-b levels. Because TGF-b is an indispensable signal for RANKLinduced ostoclastogenesis through the formation of a TRAF6/ TAB1/TAK1 molecular complex and its interaction with SMAD 3, 17 this will further contribute to impaired osteoclastogenesis. In addition, in triple 3KD tumor cells, the secretion of PTHrP was obliterated and IL11 expression severely impaired, that is, there was a sharp downregulation of two major prosteoclastogenic factors. Moreover, the response to TGF-b was severely mitigated in triple KD, which indicated that this gene subset might be cooperatively required for proper sensitivity to TGF-b signaling response. Inhibition of these mediators desensitizes tumor cells to TGF-b response and unveils a novel strategy to obliterate this vicious cycle driving osteolysis in lung cancer.
One possible explanation for the decreased activity of SMAD 2 and SMAD 3 could be induced by concurrent changes in chromatin and transcriptional regulation of several components involved in the pathway. Perturbed signaling of upstream protein kinases involved in SMAD 2/3 phosphorylation, including MAPK, CDK2/4, and others could account for these effects. 
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Complementary to this view, increased activity of phosphatases such as SCP1-3 involved in SMAD 2/3 dephosphorylation might also be required for attenuating TGF-b response. 18 Another complementary explanation, based on our findings, could be associated with an increased degradation of total SMAD 2/3 levels in triple KD cells substantiated by the finding of its posttransductional decrease upon TGF-b incubation. Thus, either directly or indirectly, it is tempting to speculate that this triple combination could regulate the baseline levels of SMAD activity expression and/or activity of kinases and/or phosphatases required for proper TGF-b signaling.
In addition to the effects derived from osteoclast activation, tumor-induced MMPs significantly contribute to bone matrix degradation. 14 We have previously shown that MMP-3/ MMP-10 activities were rapidly induced upon tumor-stromal interactions. 15 Despite the fact that type I collagen can be degraded by several MMPs, it has been recently suggested that MMP-10 is required for lung cancer stem cell maintenance and metastatic potential. 19 The fact that MMP3/10 activity was dramatically decreased in stromal coculture of 3KD cells indicated that this gene subset might also be involved in MMP signaling events driven by tumor-host interactions. Abrogation of MMP activity was only detected in coculture conditions, whereas no changes were found in cells cultured alone. These findings underscore the relevance of tumorstromal heterotypic contacts in modulating the metastatic response. It should be noted that similar tumor growth was observed in subcutaneous tumors of triple KD despite sharp differences in tumor burden observed in the osseous compartment. Therefore, modulation of cell autonomous and host-derived effects were involved in the osteolytic response and metastatic tumor growth observed in vivo.
Of the three genes, HDAC4 belongs to a class II histone deacetylase family of key regulators in growth, development 20, 21 and tumorigenesis. For instance, HDAC4 promotes growth of colon tumor cells through the inhibition of p53. 22 It also participates in cisplatin-mediated activation of STAT1, contributing to platinum chemoresistance in ovarian cancer. 23 Recently, HDAC4 has been associated in the mechanism elicited by the 'metastasisassociated protein-1', a master regulatory gene involved in prometastatic activity. 24 Similarly, PITX-1 belongs to a family of transcription factors that are also involved in development 25 and tumorigenesis. Silenced PITX1 levels in deficient p16-RAS-mutated cells resulted in an increase of tumorigenic properties. 26 This finding could explain the mild nonsignificant increase in tumor cell proliferation observed in single KD cells (data not shown). Similarly, decreased levels of PITX-1 have been detected in esophageal cancer 27 and lung cancer progression. 28 In contrast, the observation that PITX1 inhibition led to a slight decrease in bone metastasis suggests a cell context-dependent function. In this setting, it is possible that PITX-1 might be required for the secretion of tumor-derived prosteoclastogenic factors leading to tumor-induced osteolytic lesions. Moreover, the elucidation of downstream targets induced by PITX-1 requires further studies.
ROBO1 and its ligand SLIT2 have been implicated as having dual roles in tumorigenesis and metastasis. Ligand-induced ROBO1 signaling causes decreased cell-cell adhesion and elicits migratory pathways. 29, 30 In line with our findings, overexpression of ROBO1 has been detected in the metastatic signature of brain and lung metastases derived from breast cancer. 31, 32 Similarly, SLIT-ROBO signaling mediates tumor lymphatic metastasis in a model of pancreatic cancer. 33 Interestingly, TGF-b and Wnt signaling pathways 12 critical in lung AC metastases also induce ROBO1 expression 34 in agreement with our findings (Supplementary Figure S7) . Thus, ROBO1 could most likely contribute to lung cancer bone metastasis.
Intriguingly, genes that do not have an effect when singly abrogated become relevant when cooperatively depleted in HMS. This is line with previous studies supporting a collective contribution of multiple genes in the metastatic process. 35 A gene signature of TCF4, MCAM, PRKD3 y SUSD5 was involved in metastatic colonization of lung cancer to the bone in a model of large cell carcinoma. 9 None of these genes was shared by our gene signature, although both studies found identical bone tropism and similarities in osteolytic lesions and were performed using an identical methodology (Supplementary Materials and methods). This divergence among studies suggests different activities of bone colonization mechanisms, which may reflect different biological events and functions elicited by the subset of identified genes. Alternatively, different histological subtypes of tumors (large cell carcinoma vs AC) might utilize distinct set of gene signatures to accomplish cell metastatic functions.
HDAC4 and PITX1 transcript levels could predict the risk of metastasis in a clinical cohort of lung AC patients. Their cooperative contribution yields the most salient clinical outcome in two independent cohorts (Figure 7 and Supplementary  Figure S8 ), indicating that in primary tumors expression levels of these genes could be a prognostic factor for developing metastases. In this setting, ROBO1 expression levels either alone or in combination with HDAC4 and PITX1 might not have a significant role in the prediction of the clinical course of lung cancer patients. However, in late steps of metastasis recapitulated in our model system, high levels of PITX1 and HDAC4 markedly increase bone metastatic activity despite the most significant effects on metastasis occurred with the triple gene combination. Indeed, ROBO1 contributed to promote aggressive bone lesions in combination with HDAC4/PITX1, as triple gene abrogation resulted in a significant decrease in osseous metastatic burden and lesion area as compared with mice inoculated with double HDAC4/PITX1-silenced tumor cells (data not shown). The contribution of ROBO1 in the triple-silenced combination to the osteolytic lesions is also supported by the finding of a marked decrease in TGF-b response in these cells as compared with double HDAC4/PITX1-KD cells (Figure 6b and Supplementary Figure S6b) .
Thus, the use of these markers could have a clinical benefit in the outcome of these patients, but rigorous assessment of their clinical relevance requires further studies in other independent series. It is worth noting that triple stable inhibition was able to extend animal survival and preserve body weight in the experimental setting preventing tumor-induced cachexia. This daunting clinical complication associated with metastasis progression is frequently observed in different lung cancer cell models. 15, 36 The finding that PTHrP inhibition allowed partial restoration of parameters associated with cachexia such as weight or serum calcium levels without affecting tumor weight 37 could partially explain our results. Most likely, other pro-cachectic factors might also be regulated by the triple gene subset.
In summary, we have identified a set of genes mediating osseous colonization. Together with clinical observations, our data collectively support the role of these genes as combined factors with potential clinical value in lung AC. Future studies will address the impact of these findings to predict risk of metastasis progression and will ultimately evaluate patient benefits. Western blot analysis Cells were lysed in protein extraction buffer (pH 7.4, 25 mM sodium b-glycerophosphate, 1 mM Na 2 P 3 O 4 , 1 mM benzamidine, 5 mM EDTA, 5 mM EGTA, 0.05% sodium deoxycholate, 0.01% SDS, 1% Triton X-100, 10% glycerol, 0.1% b-mercaptoethanol, 1 mM sodium orthovanadate and 25 mM NaF; all reagents from Sigma) plus a protease inhibitor cocktail (Roche, Basel, Switzerland). Lysates were then centrifuged at 9000 r.p.m. using a tabletop centrifuge and protein-containing supernatants were collected. Protein concentration was determined using a Bradford assay (Bio-Rad, Hercules, CA, USA). For western blotting, 20-40 mg total protein was electrophoresed in polyacrylamide gels (Bio-Rad). After electrophoresis, protein was electroblotted onto nitrocellulose membranes (Bio-Rad). Membranes were then blocked in 5% skimmed milk solution (buffered in TBS-0.05% Tween) and incubated overnight with primary antibodies directed against phospho-Smad2 (1:2000), phospho-Smad3 (1:1000), Smad2/3 (1:2000), PITX1 (1:1000), HDAC4 (1:1100) and b-actin (1:5000). After overnight incubation, blots were washed three times with TBSTween and incubated with HRP-linked secondary antibodies against rabbit or mouse immunoglobulins (Amersham, Bucks, UK) for 1 h at room temperature. Membranes were washed four times with TBS-Tween and treated for 5 min with the peroxidase substrate LumiLight Plus (Roche). Blots were exposed to ECL films (Amersham) for 1 min and developed.
MATERIALS AND METHODS Reagents
In silico analysis
Metastasis-free survival analysis was performed using expression and clinical data available at http://www.cbio.mskcc.org/Public/lung_array_-data/ (Gerald experiment). The main features of this cohort are summarized in Supplementary Table S2 . For single probe set studies, normalized expression values from microarray experiments were divided in high-and low-expression groups using median as cutoff. For multiple probe set analysis, tumor samples with high levels of transcripts of interest were compared with the rest of the clinical cohort.
Statistical analysis
Log-rank test was used to calculate the statistical significance (P-value) of differences observed among Kaplan-Meier curves. To study differences in proliferation rates, tumor growth, differences in metastatic area, number of osteoclasts, number of single-cell-derived colonies and metalloproteolytic activity data were analyzed by different comparison tests. The test used for parametric analysis was ANOVA followed by Tukey Post hoc test in cases with variance homogeneity and Brown-Forsythe, whereas T2 Tamhane was used when variances were heterogeneous. For nonparametric analysis, tests of Kruskal-Wallis, Mann-Whitney with Bonferroni adjustment were used. Values were expressed as mean ± s.d. or median ± interquartile range according to parametric or nonparametric analyses. Statistical significance was defined as *Po0.05, **Po0.01 and ***Po0.001.
In vitro osteoclastogenic assay, MMP activity, and in vivo experiments have been previously described. 38 ABBREVIATIONS AC, adenocarcinoma; BLI, bioluminescence imaging; CM, conditioned medium; i.c., intracardiac; i.t., intratibial; KD, knockdown; MMP, matrix metalloprotease; SCDC, single-cell-derived colonies; TRAP, Tartrate-resistant acid phosphatase Antiosteolytic targets D Luis-Ravelo et al
